Interleukin-33 in allergy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 10, 2012, Pages 1203-1214

  Ohno, Tatsukuni ^a   Morita, Hideaki ^b,c   Arae, Ken ^c,d   Matsumoto, Kenji ^c   Nakae, Susumu ^e,f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d KYORIN UNIVERSITY   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Allergy; interleukin 1; interleukin 33

Indexed keywords

ALARMIN; CD34 ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 33 RECEPTOR; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ALLERGY; ANAPHYLAXIS; APOPTOSIS; ARTICLE; ASTHMA; ASTROCYTE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASOPHIL; CONJUNCTIVITIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DERMATITIS; ENDOTHELIUM; EOSINOPHIL; EPITHELIUM; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; LYMPHOID CELL; MACROPHAGE; MAST CELL; MICROGLIA; NATURAL KILLER T CELL; NECROSIS; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; RHINITIS; RHINOSINUSITIS; T LYMPHOCYTE; TH2 CELL;

ANIMALS; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; INTERLEUKINS; MICE;

EID: 84866440902     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12004     Document Type: Article

References (136)

1. Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S,. IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 2010; 59: 143-160.
2. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005; 23: 479-490. (Pubitemid 41587888)
3. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A 2007; 104: 282-287. (Pubitemid 46068023)
4. Roussel L, Erard M, Cayrol C, Girard JP,. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9: 1006-1012.
5. Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y, et al. The precursor form of IL-1α is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci U S A 2004; 101: 2434-2439. (Pubitemid 38269329)
6. Andersson U, Tracey KJ,. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011; 29: 139-162.
7. Dinarello CA,. Interleukin-1β, interleukin-18, and the interleukin-1β converting enzyme. Ann N Y Acad Sci 1998; 856: 1-11.
8. Dinarello CA,. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27: 519-550.
9. Talabot-Ayer D, Lamacchia C, Gabay C, Palmer G,. Interleukin-33 is biologically active independently of caspase-1 cleavage. J Biol Chem 2009; 284: 19420-19426.
10. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity 2009; 31: 84-98.
11. Cayrol C, Girard JP,. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009; 106: 9021-9026.
12. Ohno T, Oboki K, Kajiwara N, Morii E, Aozasa K, Flavell RA, et al. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J Immunol 2009; 183: 7890-7897.
13. Ali S, Huber M, Kollewe C, Bischoff SC, Falk W, Martin MU,. IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci U S A 2007; 104: 18660-18665. (Pubitemid 350210753)
14. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA,. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 2007; 179: 2551-2555.
15. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, Talabot-Ayer D, et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 2008; 42: 358-364.
16. Smith DE,. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy 2010; 40: 200-208.
17. Akira S, Takeda K, Kaisho T,. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2: 675-680. (Pubitemid 32747155)
18. Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci U S A 1998; 95: 6930-6935. (Pubitemid 28278084)
19. Lecart S, Lecointe N, Subramaniam A, Alkan S, Ni D, Chen R, et al. Activated, but not resting human Th2 cells, in contrast to Th1 and T regulatory cells, produce soluble ST2 and express low levels of ST2L at the cell surface. Eur J Immunol 2002; 32: 2979-2987. (Pubitemid 35238191)
20. Nakae S, Iwakura Y, Suto H, Galli SJ,. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 2007; 81: 1258-1268. (Pubitemid 46702045)
21. Guo L, Wei G, Zhu J, Liao W, Leonard WJ, Zhao K, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A 2009; 106: 13463-13468.
22. Xu D, Chan WL, Leung BP, Huang F, Wheeler R, Piedrafita D, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187: 787-794. (Pubitemid 28115194)
23. Kropf P, Schopf LR, Chung CL, Xu D, Liew FY, Sypek JP, et al. Expression of Th2 cytokines and the stable Th2 marker ST2L in the absence of IL-4 during Leishmania major infection. Eur J Immunol 1999; 29: 3621-3628. (Pubitemid 29527810)
24. Kropf P, Herath S, Tewari R, Syed N, Klemenz R, Muller I,. Identification of two distinct subpopulations of Leishmania major-specific T helper 2 cells. Infect Immun 2002; 70: 5512-5520.
25. Kondo Y, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Morimoto M, Hayashi N, et al. Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system. Int Immunol 2008; 20: 791-800. (Pubitemid 351791523)
26. Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY,. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol 2007; 37: 2779-2786. (Pubitemid 47578297)
27. + T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. J Immunol 1999; 162: 3882-3889. (Pubitemid 29314766)
28. Hoshino K, Kashiwamura S, Kuribayashi K, Kodama T, Tsujimura T, Nakanishi K, et al. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med 1999; 190: 1541-1548.
29. Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN,. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med 2000; 191: 1069-1076.
30. Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci U S A 2010; 107: 18581-18586.
31. + T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181: 4780-4790.
32. Blom L, Poulsen BC, Jensen BM, Hansen A, Poulsen LK,. IL-33 induces IL-9 production in human CD4 + T cells and basophils. PLoS ONE 2011; 6: e21695.
33. + T cells. Eur J Immunol 2010; 40: 2230-2235.
34. McGuirk P, McCann C, Mills KH,. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002; 195: 221-231. (Pubitemid 34461266)
35. Chan WL, Pejnovic N, Lee CA, Al-Ali NA,. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J Immunol 2001; 167: 1238-1244. (Pubitemid 32703118)
36. + T cells. Eur J Immunol 2011; 41: 3351-3360.
37. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE,. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol 2008; 20: 1019-1030.
38. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol 2009; 39: 1046-1055.
39. Bourgeois EA, Levescot A, Diem S, Chauvineau A, Berges H, Milpied P, et al. A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation. Eur J Immunol 2011; 41: 299-305.
40. Dorshkind K, Montecino-Rodriguez E,. Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. Nat Rev Immunol 2007; 7: 213-219.
41. Martin F, Oliver AM, Kearney JF,. Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens. Immunity 2001; 14: 617-629. (Pubitemid 32520872)
42. Komai-Koma M, Gilchrist DS, McKenzie AN, Goodyear CS, Xu D, Liew FY,. IL-33 activates B1 cells and exacerbates contact sensitivity. J Immunol 2011; 186: 2584-2591.
43. Takatsu K, Kouro T, Nagai Y,. Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol 2009; 101: 191-236.
44. Ho LH, Ohno T, Oboki K, Kajiwara N, Suto H, Iikura M, et al. IL-33 induces IL-13 production by mouse mast cells independently of IgE-FcepsilonRI signals. J Leukoc Biol 2007; 82: 1481-1490. (Pubitemid 350276960)
45. Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y, et al. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest 2007; 87: 971-978. (Pubitemid 47429189)
46. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G,. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol 2007; 179: 2051-2054.
47. Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R,. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J Immunol 1998; 161: 4866-4874. (Pubitemid 28492065)
48. Moulin D, Donze O, Talabot-Ayer D, Mezin F, Palmer G, Gabay C,. Interleukin (IL)-33 induces the release of pro-inflammatory mediators by mast cells. Cytokine 2007; 40: 216-225. (Pubitemid 350213434)
49. Kaieda S, Shin K, Nigrovic PA, Seki K, Lee RT, Stevens RL, et al. Synovial fibroblasts promote the expression and granule accumulation of tryptase via interleukin-33 and its receptor ST-2 (IL1RL1). J Biol Chem 2010; 285: 21478-21486.
50. Pushparaj PN, Tay HK, H'Ng SC, Pitman N, Xu D, McKenzie A, et al. The cytokine interleukin-33 mediates anaphylactic shock. Proc Natl Acad Sci U S A 2009; 106: 9773-9778.
51. Silver MR, Margulis A, Wood N, Goldman SJ, Kasaian M, Chaudhary D,. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res 2010; 59: 207-218.
52. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol 2011; 41: 2229-2237.
53. Pecaric-Petkovic T, Didichenko SA, Kaempfer S, Spiegl N, Dahinden CA,. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood 2009; 113: 1526-1534.
54. Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A, et al. An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol 2008; 181: 5981-5989.
55. Schneider E, Petit-Bertron AF, Bricard R, Levasseur M, Ramadan A, Girard JP, et al. IL-33 activates unprimed murine basophils directly in vitro and induces their in vivo expansion indirectly by promoting hematopoietic growth factor production. J Immunol 2009; 183: 3591-3597.
56. Kroeger KM, Sullivan BM, Locksley RM,. IL-18 and IL-33 elicit Th2 cytokines from basophils via a MyD88- and p38alpha-dependent pathway. J Leukoc Biol 2009; 86: 769-778.
57. Suzukawa M, Koketsu R, Iikura M, Nakae S, Matsumoto K, Nagase H, et al. Interleukin-33 enhances adhesion, CD11b expression and survival in human eosinophils. Lab Invest 2008; 88: 1245-1253.
58. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H,. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol 2008; 121: 1484-1490. (Pubitemid 351787349)
59. Chow JY, Wong CK, Cheung PF, Lam CW,. Intracellular signaling mechanisms regulating the activation of human eosinophils by the novel Th2 cytokine IL-33: implications for allergic inflammation. Cell Mol Immunol 2010; 7: 26-34.
60. Roth N, Stadler S, Lemann M, Hosli S, Simon HU, Simon D,. Distinct eosinophil cytokine expression patterns in skin diseases-the possible existence of functionally different eosinophil subpopulations. Allergy 2011; 66: 1477-1486.
61. Mayuzumi N, Matsushima H, Takashima A,. IL-33 promotes DC development in BM culture by triggering GM-CSF production. Eur J Immunol 2009; 39: 3331-3342.
62. Rank MA, Kobayashi T, Kozaki H, Bartemes KR, Squillace DL, Kita H,. IL-33-activated dendritic cells induce an atypical TH2-type response. J Allergy Clin Immunol 2009; 123: 1047-1054.
63. Besnard AG, Togbe D, Guillou N, Erard F, Quesniaux V, Ryffel B,. IL-33-activated dendritic cells are critical for allergic airway inflammation. Eur J Immunol 2011; 41: 1675-1686.
64. Steinman RM,. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30: 1-22.
65. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y,. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun 2002; 299: 18-24. (Pubitemid 35366029)
66. Sweet MJ, Leung BP, Kang D, Sogaard M, Schulz K, Trajkovic V, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Toll-like receptor 4 expression. J Immunol 2001; 166: 6633-6639. (Pubitemid 32467204)
67. Espinassous Q, Garcia-de-Paco E, Garcia-Verdugo I, Synguelakis M, von Aulock S, Sallenave JM, et al. IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex. J Immunol 2009; 183: 1446-1455.
68. Kumar S, Tzimas MN, Griswold DE, Young PR,. Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. Biochem Biophys Res Commun 1997; 235: 474-478. (Pubitemid 27326503)
69. Saccani S, Polentarutti N, Penton-Rol G, Sims JE, Mantovani A,. Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo. Cytokine 1998; 10: 773-780. (Pubitemid 28495228)
70. Joshi AD, Oak SR, Hartigan AJ, Finn WG, Kunkel SL, Duffy KE, et al. Interleukin-33 contributes to both M1 and M2 chemokine marker expression in human macrophages. BMC Immunol 2010; 11: 52.
71. Kurowska-Stolarska M, Stolarski B, Kewin P, Murphy G, Corrigan CJ, Ying S, et al. IL-33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J Immunol 2009; 183: 6469-6477.
72. Miller AM, Asquith DL, Hueber AJ, Anderson LA, Holmes WM, McKenzie AN, et al. Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice. Circ Res 2011; 107: 650-658.
73. Ohno T, Oboki K, Morita H, Kajiwara N, Arae K, Tanaka S, et al. Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation. PLoS ONE 2011; 6: e18404.
74. Brint EK, Xu D, Liu H, Dunne A, McKenzie AN, O'Neill LA, et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004; 5: 373-379. (Pubitemid 38500085)
75. Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res 2011; 26: 704-717.
76. Saidi S, Bouri F, Lencel P, Duplomb L, Baud'huin M, Delplace S, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 2011; 53: 347-354.
77. Saleh H, Eeles D, Hodge JM, Nicholson GC, Gu R, Pompolo S, et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 2011; 152: 1911-1922.
78. + monocytes. Cell Mol Life Sci 2010; 67: 3883-3892.
79. Zaiss MM, Kurowska-Stolarska M, Bohm C, Gary R, Scholtysek C, Stolarski B, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-α-mediated bone loss. J Immunol 2011; 186: 6097-6105.
80. Andre R, Lerouet D, Kimber I, Pinteaux E, Rothwell NJ,. Regulation of expression of the novel IL-1 receptor family members in the mouse brain. J Neurochem 2005; 95: 324-330. (Pubitemid 41457501)
81. Yasuoka S, Kawanokuchi J, Parajuli B, Jin S, Doi Y, Noda M, et al. Production and functions of IL-33 in the central nervous system. Brain Res 2011; 1385: 8-17.
82. Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT,. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008; 84: 631-643.
83. Allakhverdi Z, Comeau MR, Smith DE, Toy D, Endam LM, Desrosiers M, et al. CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009; 123: 472-478.
84. + lymphoid cells. Nature 2010; 463: 540-544.
85. Koyasu S, Moro K,. Type 2 innate immune responses and the natural helper cell. Immunology 2011; 132: 475-481.
86. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464: 1367-1370.
87. Saenz SA, Siracusa MC, Perrigoue JG, Spencer SP, Urban JF Jr, Tocker JE, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010; 464: 1362-1366.
88. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A 2010; 107: 11489-11494.
89. Saenz SA, Noti M, Artis D,. Innate immune cell populations function as initiators and effectors in Th2 cytokine responses. Trends Immunol 2010; 31: 407-413.
90. Barlow JL, McKenzie AN,. Nuocytes: expanding the innate cell repertoire in type-2 immunity. J Leukoc Biol 2011; 90: 867-874.
91. Koyasu S, Moro K,. Innate Th2-type immune responses and the natural helper cell, a newly identified lymphocyte population. Curr Opin Allergy Clin Immunol 2011; 11: 109-114.
92. Liang HE, Reinhardt RL, Bando JK, Sullivan BM, Ho IC, Locksley RM,. Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. Nat Immunol 2011; 13: 58-66.
93. Wilhelm C, Hirota K, Stieglitz B, Van Snick J, Tolaini M, Lahl K, et al. An IL-9 fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011; 12: 1071-1077.
94. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012; 129: 191-198. e1-4.
95. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011; 12: 631-638.
96. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12: 1045-1054.
97. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055-1062.
98. Choi YS, Choi HJ, Min JK, Pyun BJ, Maeng YS, Park H, et al. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood 2009; 114: 3117-3126.
99. Yagami A, Orihara K, Morita H, Futamura K, Hashimoto N, Matsumoto K, et al. IL-33 mediates inflammatory responses in human lung tissue cells. J Immunol 2010; 185: 5743-5750.
100. Aoki S, Hayakawa M, Ozaki H, Takezako N, Obata H, Ibaraki N, et al. ST2 gene expression is proliferation-dependent and its ligand, IL-33, induces inflammatory reaction in endothelial cells. Mol Cell Biochem 2010; 335: 75-81.
101. Demyanets S, Konya V, Kastl SP, Kaun C, Rauscher S, Niessner A, et al. Interleukin-33 induces expression of adhesion molecules and inflammatory activation in human endothelial cells and in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2011; 31: 2080-2089.
102. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A 2010; 107: 8017-8022.
103. Fujita J, Kawaguchi M, Kokubu F, Ohara G, Ota K, Huang SK, et al. Interleukin-33 induces interleukin-17F in bronchial epithelial cells. Allergy 2012; 67: 744-750.
104. Tominaga S,. Murine mRNA for the beta-subunit of integrin is increased in BALB/c-3T3 cells entering the G1 phase from the G0 state. FEBS Lett 1988; 238: 315-319.
105. Kurokawa M, Matsukura S, Kawaguchi M, Ieki K, Suzuki S, Odaka M, et al. Expression and effects of IL-33 and ST2 in allergic bronchial asthma: IL-33 induces eotaxin production in lung fibroblasts. Int Arch Allergy Immunol 2011; 155 (Suppl 1): 12-20.
106. Gudbjartsson DF, Bjornsdottir US, Halapi E, Helgadottir A, Sulem P, Jonsdottir GM, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat Genet 2009; 41: 342-347.
107. Oshikawa K, Kuroiwa K, Tago K, Iwahana H, Yanagisawa K, Ohno S, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164: 277-281. (Pubitemid 34001295)
108. Ali M, Zhang G, Thomas WR, McLean CJ, Bizzintino JA, Laing IA, et al. Investigations into the role of ST2 in acute asthma in children. Tissue Antigens 2009; 73: 206-212.
109. Prefontaine D, Lajoie-Kadoch S, Foley S, Audusseau S, Olivenstein R, Halayko AJ, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183: 5094-5103.
110. Prefontaine D, Nadigel J, Chouiali F, Audusseau S, Semlali A, Chakir J, et al. Increased IL-33 expression by epithelial cells in bronchial asthma. J Allergy Clin Immunol 2010; 125: 752-754.
111. Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y,. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. Clin Exp Allergy 2002; 32: 1520-1526. (Pubitemid 35278923)
112. Hayakawa H, Hayakawa M, Kume A, Tominaga S,. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem 2007; 282: 26369-26380. (Pubitemid 47443815)
113. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P, et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012; 129: 216-227.
114. Wills-Karp M, Rani R, Dienger K, Lewkowich I, Fox JG, Perkins C, et al. Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection. J Exp Med 2012; 209: 607-622.
115. Mangan NE, Dasvarma A, McKenzie AN, Fallon PG,. T1/ST2 expression on Th2 cells negatively regulates allergic pulmonary inflammation. Eur J Immunol 2007; 37: 1302-1312. (Pubitemid 46925314)
116. Oboki K, Ohno T, Saito H, Nakae S,. Th17 and allergy. Allergol Int 2008; 57: 121-134. (Pubitemid 351897666)
117. Besnard AG, Guillou N, Tschopp J, Erard F, Couillin I, Iwakura Y, et al. NLRP3 inflammasome is required in murine asthma in the absence of aluminum adjuvant. Allergy 2011; 66: 1047-1057.
118. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol 2011; 23: 307-315.
119. Johnson JR, Wiley RE, Fattouh R, Swirski FK, Gajewska BU, Coyle AJ, et al. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. Am J Respir Crit Care Med 2004; 169: 378-385. (Pubitemid 38134818)
120. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN,. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 2009; 15: 410-416.
121. Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R, et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009; 457: 585-588.
122. Milne J, Brand S,. Occupational asthma after inhalation of dust of the proteolytic enzyme, papain. Br J Ind Med 1975; 32: 302-307.
123. Halim TY, Krauss RH, Sun AC, Takei F,. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012; 36: 451-463.
124. Reese TA, Liang HE, Tager AM, Luster AD, Van Rooijen N, Voehringer D, et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. Nature 2007; 447: 92-96. (Pubitemid 46685837)
125. Yasuda K, Muto T, Kawagoe T, Matsumoto M, Sasaki Y, Matsushita K, et al. Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A 2012; 109: 3451-3456.
126. Sakashita M, Yoshimoto T, Hirota T, Harada M, Okubo K, Osawa Y, et al. Association of serum interleukin-33 level and the interleukin-33 genetic variant with Japanese cedar pollinosis. Clin Exp Allergy 2008; 38: 1875-1881.
127. Castano R, Bosse Y, Endam LM, Desrosiers M,. Evidence of association of interleukin-1 receptor-like 1 gene polymorphisms with chronic rhinosinusitis. Am J Rhinol Allergy 2009; 23: 377-384.
128. Hong YS, Moon SJ, Joo YB, Jeon CH, Cho ML, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci 2011; 26: 1132-1139.
129. Kim YH, Yang TY, Park CS, Ahn SH, Son BK, Kim JH, et al. Anti-IL-33 antibody has a therapeutic effect in a murine model of allergic rhinitis. Allergy 2012; 67: 183-190.
130. Matsuda A, Okayama Y, Terai N, Yokoi N, Ebihara N, Tanioka H, et al. The role of interleukin-33 in chronic allergic conjunctivitis. Invest Ophthalmol Vis Sci 2009; 50: 4646-4652.
131. Matsuba-Kitamura S, Yoshimoto T, Yasuda K, Futatsugi-Yumikura S, Taki Y, Muto T, et al. Contribution of IL-33 to induction and augmentation of experimental allergic conjunctivitis. Int Immunol 2010; 22: 479-489.
132. Shimizu M, Matsuda A, Yanagisawa K, Hirota T, Akahoshi M, Inomata N, et al. Functional SNPs in the distal promoter of the ST2 gene are associated with atopic dermatitis. Hum Mol Genet 2005; 14: 2919-2927. (Pubitemid 41418796)
133. Paliwal V, Tsuji RF, Szczepanik M, Kawikova I, Campos RA, Kneilling M, et al. Subunits of IgM reconstitute defective contact sensitivity in B-1 cell-deficient xid mice: kappa light chains recruit T cells independent of complement. J Immunol 2002; 169: 4113-4123. (Pubitemid 35178180)
134. Itakura A, Kikuchi Y, Kouro T, Ikutani M, Takaki S, Askenase PW, et al. Interleukin 5 plays an essential role in elicitation of contact sensitivity through dual effects on eosinophils and B-1 cells. Int Arch Allergy Immunol 2006; 140 (Suppl 1): 8-16. (Pubitemid 43882379)
135. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C, Alexander J, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naive mice. Allergy 2012. doi: 10.1111/j.1398-9995.2012.02859.x. [Epub ahead of print]
136. Hsu CL, Neilsen CV, Bryce PJ,. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS One 2010; 5: e11944.